Clinical Pharmacology of Cytokine Release Syndrome with T-Cell-Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies.

For most T-BiSp, there was a positive trend between Cmax/ROmax and the probability of CRS at SUDs and FD1 if enough CRS events were present ( Table 3 ; Supplementary Fig.

also in 11,005 other papers